@entity419 positron emission tomography (FDG-PET) scans in the first 49 @entity1 referred with either possible @entity1313 or @entity1313 recurrence were reviewed. FDG-PET imaging was reported with reference to anatomical imaging. Based on the report the FDG study was classified as either positive or negative for the presence of @entity5 . Thirty-eight cases were included in the analysis, 21 having pathological data and 17 with diagnostic clinical follow up. Eleven were excluded, as they had inadequate follow-up data. Of the 21 cases with pathology, 18 were shown to have @entity5 . In this group there were five false-negative scans and two false-positive PET scans. Seventeen cases were assessed by clinical follow up, nine were considered to have been @entity5 . There were two false negatives with one false positive. The overall sensitivity, specificity and positive and negative predictive values were 74, 73, 87 and 53% respectively. This is similar to figures previously quoted in published work. Despite relatively limited numbers, the utility of FDG PET imaging in our hands is similar to published reports. With a positive predictive value of 87%, a positive FDG study indicates a high likelihood that there is @entity1313 present. A negative study does not exclude the presence of @entity5 .

@entity419 positron emission tomography imaging in XXXX : the Western Australia positron emission tomography/cyclotron service experience.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour'] @entity419 :: ('MESH:D019788', 'Chemical') :: ['(18)F-fluorodeoxyglucose'] @entity1313 :: ('MESH:D001932', 'Disease') :: ['brain tumour']
@entity1313 :: (MESH:D001932,Disease) :: ['brain tumours']
